Clinical trials: CtDNA
Neoplasms, Cancer
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early.
- Trial name
- NCT03085888
- Where
- 35 sites in United States
- Volunteers
- 99,481 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Lung Nodule
Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients
Low-dose computed tomography (LDCT) is recommended for early-stage lung cancer screening. However, it is often difficult to determine indolent lesions from more aggressive tumors without an invasive intervention or prolonged…
- Trial name
- NCT03685669
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Colorectal Adenoma, Colorectal Cancer
Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial Intelligence
To evaluate the accuracy and effectiveness of a novel screening method based on plasma multi-omics combining with artificial intelligence in a large prospective cohort for the detection of colorectal cancer and advanced adenomas.
- Trial name
- RECOMMEND (NCT05587452)
- Testing
- Colonoscopy, Test of ctDNA methylation, Test of characteristics of ctDNA fragment
- Where
- 5 sites in China
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer, Colorectal Adenoma
A Study on a Blood-based Dual-target Test for CRC Detection
To evaluate the effectiveness and accuracy of the ctDNA dual-target test kit in a large case-control cohort for the detection of colorectal cancer and advanced adenomas.
- Trial name
- NCT05508503
- Testing
- Test of methylated NTMT1 and MAP3K14-AS1, FIT
- Where
- China
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Cancer
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers.
- Trial name
- NHS-Galleri (NCT05611632)
- Testing
- Multi-cancer early detection test (Galleri test)
- Where
- United Kingdom
- Volunteers
- 142,318 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Colon Cancer, Colon Adenomas
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream.
- Conditions
- Colon Cancer, Colon Adenomas, Colon Polyps
- Trial name
- NCT02665299
- Where
- United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Pathway Genomics
Colorectal Cancer, Adenoma
The Implication of Plasma ctDNA Methylation Haplotypes in Detecting Colorectal Cancer and Adenomas
This is a multicenter, clinical study. This study is to evaluate the sensitivity of plasma ctDNA methylation haplotypes in detecting colorectal cancer, adenoma and the specificity in healthy individuals.
- Trial name
- NCT03737591
- Testing
- Next-generation sequencing (NGS)
- Where
- China
- Volunteers
- 1,138 people, healthy volunteers welcome
- Sponsor
- Fudan University
Cancer
Galleri® in the Medicare Population.
This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test.
- Trial name
- NCT05673018
- Testing
- Multi-Cancer Early Detection Test (Galleri®)
- Where
- 72 sites in United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return.
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
- Trial name
- NCT04585477
- Testing
- AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Stanford University
Gastric Cancer
ctDNA-MRD Monitoring After Resection in Gastric Cancer
Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and…
- Trial name
- MRD-GC (NCT06893133)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Peking University
Neoplasms, Cancer
The Circulating Cell-free Genome Atlas Study
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood.
- Trial name
- CCGA (NCT02889978)
- Where
- 140 sites in United States, Canada
- Volunteers
- 15,254 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Colorectal Cancer, Colorectal Adenoma
Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer
CoLiQ is a clinical study designed to evaluate the clinical usefulness of circulating tumor DNA (ctDNA) markers found in blood, as a liquid biopsy for diagnosis, prognosis and follow-up of colorectal cancer.
- Trial name
- CoLiQ (NCT06307938)
- Testing
- liquid biopsy
- Where
- Norway
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Helse Nord-Trøndelag HF
Multiple Myeloma
ctDNA Methylation Sequencing for Myeloma
1. To carry out research on minimal residual disease (MRD) monitoring in patients with multiple myeloma (MM) based on plasma circulating tumor DNA (ctDNA) methylation sequencing, which aims to explore new MRD detection methods…
- Trial name
- NCT05578625
- Testing
- plasma circulation DNA methylation sequencing
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Epithelial Ovarian Cancer
Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.
Epithelial ovarian cancer constitutes one of the most common gynecological malignancies.Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an…
- Trial name
- ctDNA_EOC (NCT03155451)
- Testing
- methylation markers screening
- Where
- China
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Non Small Cell Lung Cancer
Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer
This observational study will evaluate whether a blood test can detect the return of non-small cell lung cancer at least three months before it is identified on routine imaging.
- Trial name
- NCT07854769
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Colorectal Cancer
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization.
- Trial name
- ECLIPSE (NCT04136002)
- Where
- 271 sites in United States
- Volunteers
- 44,467 people, healthy volunteers welcome
- Sponsor
- Guardant Health, Inc.
Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
Biliary tract carcinoma (BTC), including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, ranks sixth in incidence among gastrointestinal malignancies and tenth in cancer-related mortality…
- Conditions
- Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma
- Trial name
- NCT07176962
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Yingbin Liu, MD, PhD, FACS
Esophageal Squamous Cell Carcinoma
Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer
The aim of this study was to detect the whole genome hydroxymethylation of peripheral blood ct DNA in normal population, patients with p0~pI esophageal squamous cell carcinoma and pII~pIV esophageal squamous cell carcinoma by…
- Trial name
- NCT03922230
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University